Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Sign Up to like & getrecommendations! Published in 2018 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2017.10.023
Abstract: Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly potent integrase inhibitor, with a half-life of up to 54 days,… read more here.
Keywords: creation nanoformulated; prodrug improved; nanoformulated cabotegravir; cab ... See more keywords